Navigation Links
Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
Date:10/4/2007

s / Nestle Pre-Clinical Studies

The final results of the two pre-clinical dose response trials announced to the market on December 14th, 2006, confirmed that when given orally, Phospha E(R) significantly reduced many of the key biomarkers associated with metabolic syndrome, inflammation and cardiovascular disease. Additionally, the most appropriate dosage required to commence human clinical trials was also determined. In these trials, animals treated with varying doses of Phospha E were shown to have statistically significant reductions in key parameters such as plaque formation, aortic vascular dysfunction, cholesterol, triglycerides and LDL-C (so called bad cholesterol).

About Metabolic Syndrome

Metabolic syndrome is characterized by a group of metabolic risk factors - abdominal obesity and elevated blood pressure, cholesterol, triglycerides and blood glucose. The root causes of metabolic syndrome are overweight/obesity, physical inactivity, and genetic factors. It is estimated that about 27% of adults in the US have metabolic syndrome and that one in three overweight or obese people in the US have this condition. The condition is being diagnosed with increasing frequency.

About Phospha E(R)

Phospha E(R) is a patented derivative of vitamin E that has superior properties compared to its parent molecule. For example, Phospha E has been shown to be better absorbed than vitamin E, both orally and through the skin, to lower cholesterol and triglycerides, prevent the formation of plaque in heart arteries, as well as having unique anti-inflammatory properties. Phospha E has applications across all three nutraceutical market segments, and is currently sold internationally as a dietary supplement by NBTY Inc. (under the name of Ester-E(TM)) and is marketed worldwide in the personal care market as Vital ET(TM) by ISP Corporation.

Safe Harbor Statement

This press release contains forward-looking statements based on current expectatio
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
2. Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
6. AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Kan. , July 25, 2014 /PRNewswire-iReach/ -- ... and TCGRx, of Powers Lake, Wisconsin ... partners in a distribution and co-marketing agreement allowing ... retail pharmacies throughout the United States ... robotics-based pharmacy management and workflow systems to retail ...
(Date:7/25/2014)... , July 25, 2014  CVS Caremark Corporation (NYSE: ... call on Tuesday, August 5, 2014, at 8:30 a.m. ... quarter 2014 financial results. An audio webcast ... the Investor Relations portion of the CVS Caremark website ... http://info.cvscaremark.com/investors . This webcast will be archived and ...
(Date:7/25/2014)... Trinidad and Tobago , July 25, 2014 ... the Trinidad & Tobago Ministry of Health approved ... therapy that significantly increases the cure rate from ... infected with the genotype 1 virus. Telaprevir is ... the trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... The University of Oxford Clinical Trial,Service Unit ... results of the SEAS trial of ezetimibe should ... the SHARP and,IMPROVE-IT trials of ezetimibe, and reporting ... independently of the drug,manufacturers., The two hypothesis-testing ...
... clinicians identify risk in patients, including ... BIRMINGHAM, Ala., July 21 Using the ... link between,adiponectin and heart disease progression. The information ... cholesterol and heart,disease risk-lowering treatments in at-risk patients., ...
Cached Medicine Technology:Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 2VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis 3
(Date:7/25/2014)... neurons and reduce motor deficits in a rat ... School of Medicine have shown. , The results ... Disease . , The findings demonstrate that the ... sufficient levels and have beneficial effects when administered ... studies of XPro1595 in animals tested more invasive ...
(Date:7/25/2014)... announced the launch of its ASA Perioperative Surgical ... to improve the patient experience before, during and ... care organizations from across the country will participate ... first time at the ASA,s PSH Learning Collaborative ... PSH collaborative participants will create a network where ...
(Date:7/25/2014)... Florida (PRWEB) July 25, 2014 ... its co-founders, professional stuntman and parkour instructor, Jared “JJ” ... extreme sports competition show, American Ninja Warrior. The show ... 28th at 9PM and will rerun on the new ... Woods, a long-time Miami resident, has been balancing careers ...
(Date:7/25/2014)... NJ (PRWEB) July 25, 2014 CarePoint ... Dr. Edward Boylan, has joined our network, CarePoint ... the community. Hundreds of highly skilled and experienced physicians ... top doctors and practices in Hudson County, representing a ... Health’s commitment to provide the highest quality care to ...
(Date:7/25/2014)... Eye & Vision has announced the celebration ... by expanding a new specialized ocular and vision service ... clinic. , By acquiring specialized Visual Evoked Potential (VEP) ... problems, patients with vision loss in need of visual ... implementation of this specialized vision testing clinic. The new ...
Breaking Medicine News(10 mins):Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 2Health News:ASA launches national Perioperative Surgical Home learning collaborative 3Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 2Health News:Eye & Vision, a Leading Eye Doctor Group in Richardson, Celebrate Milestone and Expand Scope of Specialized Eye Care 3
... belief that adolescent boys tend to take romance for a ... to heart matters, they might not be so fleeting after ... outside, an adolescent boy fails to communicate his emotions, leading ... ,Boys are more vulnerable and emotionally engaged in romantic ...
... at the University of California, appearing in the latest ... says that people// with autism never "daydream" The researchers ... of people having autism and those not affected by ... the brain, emotions and thoughts are processed. However this ...
... India Institute of Medical Sciences (AIIMS) here is running short ... than sanctioned//, Rajya Sabha was informed Friday. ,Replying to ... Panabaka Lakshmi said that the AIIMS was running with just ... ,She also informed the house that during 2003-05, ...
... Economy Research Institute at the University of Massachusetts listed ... air pollution//. This list is officially called the Toxic ... source of air pollution. This is based on air ... the United States. , The various factors ...
... in Australia's medical schools have become so inadequate that ... parts even confusing// certain vital organs with each other. ... have raised concerns that medical students are not being ... the students are not properly trained in anatomy. According ...
... of Medical Sciences (RIMS) is organising a three-day intensive ... states from today// the 11th April. This course is ... the shortfall of sports medicine specialists in the Northeast; ... ,Professor L Fimate the RIMS director, while addressing ...
Cached Medicine News:Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 3
... Mapping. Biosense Webster offers a complete ... SANTORO Fixed Catheter is designed for ... the coronary sinus. The pair of ... tip permit pacing in the coronary ...
Standard Deflectable Catheters...
... Soft HIS diagnostic catheters provide ... designed curve that allows for ... HIS bundle. In addition, the ... reduce the risk of perforation ...
The Explorer 360 and 360 Jr. catheters have a rotational connector for ease of use during procedures....
Medicine Products: